Company says it will begin paying annual dividends
Hvivo
New and existing institutional investors indicated demand for shares was in excess of those available
Pharmaceutical services company is testing drug for human rhinovirus in human challenge trial
Company, formerly known as Open Orphan, described the first half of 2023 as ‘another period of excellent growth’
Dublin- and London-listed pharma services company has seen its order book grow 11% in first half from same period in 2022
Deal is Dublin-listed pharma company's first in the region in over 10 years
Company expects revenues from the contract to be recognised across 2022 and 2023
Bavarian Nordic vaccine candidate used hVivo challenge trial to gather data
Executive chairman Cathal Friel said Hvivo expects to sign a number of similar contracts
Healthy volunteers are administered a pathogenic or virulent strain of virus
hVivo will develop a new SARS-CoV-2 challenge virus based on new emerging variants
Contract with US biotechnology company concerns a respiratory syncytial virus
Irish clinical trials group will deliberately infect healthy young volunteers with virus
Guidelines will cover manufacture of agents for use in controlled infection studies
YOU MAY ALSO LIKE...
How does a post-Brexit world shape the identity and relationship of these islands
Inquests into the nightclub fire that led to the deaths of 48 people
Weddings, Births, Deaths and other family notices